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Abstract
HIV-1 Nef protein down-regulates several cell surface receptors through its interference with the cell sorting and trafficking
machinery. Here we demonstrate for the first time the ability of Nef to down-regulate cell surface expression of the negative
immune modulator CTLA-4. Down-regulation of CTLA-4 required the Nef motifs DD175, EE155 and LL165, all known to be
involved in vesicle trafficking. Disruption of the lysosomal functions by pH-neutralizing agents prevented CTLA-4 down-
regulation by Nef, demonstrating the implication of the endosomal/lysosomal compartments in this process. Confocal
microscopy experiments visualized the co-localization between Nef and CTLA-4 in the early and recycling endosomes but
not at the cell surface. Overall, our results provide a novel mechanism by which HIV-1 Nef interferes with the surface
expression of the negative regulator of T cell activation CTLA-4. Down-regulation of CTLA-4 may contribute to the
mechanisms by which HIV-1 sustains T cell activation, a critical step in viral replication and dissemination.
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Introduction
HIV-1 regulatory viral proteins such as Nef, Vif, Vpr and Vpu
create a cellular environment that is favorable for viral replication
and dissemination [1]. Of particular importance, Nef plays a
critical role in modulating the cellular microenvironment required
for efficient viral replication by down-regulating multiple cell
surface molecules through its interference with the intracellular
sorting machinery [2,3]. Nef-mediated down-regulation of CD4,
the major HIV receptor, prevents superinfection during the early
and late stages of infection as well as formation of the viral Env
protein/CD4 oligomers during the budding process [4,5,6,7,8,9].
Nef also down-regulates MHC class I molecules in infected cells,
likely preventing their killing by cytotoxic CD8 T cells [10].
Expression of Nef enhances HIV-1 production by interacting with
PI3k and p21-activated kinase2 (PAK2) [11,12]. In addition, Nef is
known to modulate several pathways of cell signaling and protects
infected cells from apoptosis through the phosphorylation and
inactivation of Bad, a proapoptotic member of the Bcl-2 protein
family [13]. Moreover, the presence of Nef alters T cell activation
through its interaction with the T cell-specific tyrosine kinase Lck
via a conserved proline-rich repeat sequence {(PxxP)4} [14,15,16].
Nef has also been reported to play a critical role in the early
activation of infected cells by sensitizing TCR to stimulation,
thereby promoting secretion of the major T cell growth factor IL-2
and HIV replication [17,18]. However, stimulation of T cells via
TCR and CD28 leads to the up-regulation of molecules such as
CTLA-4, which are known to negatively regulate cell activation
[19] and potentially HIV replication. CTLA-4 is a cell surface
protein that interacts with its ligands CD80 (B7-1) and CD86 (B7-
2) expressed on APCs and stops T cell activation and IL-2
production [20,21]. CTLA-4 is also essential for the suppressive
functions of Tregs [22] and the induction of indoleamine 2,3-
dioxygenase (IDO) in tolergenic dendritic cells [23]. CTLA-4 is
found mainly as an intracellular protein that resides in endocytic
vesicles and secretory granules [24,25]. Surface expression of
CTLA-4 is regulated by tyrosine motifs embedded within its
cytoplasmic tail and mediate CTLA-4 binding to the m2 subunit of
the adaptor sorting protein AP2. Following TCR stimulation,
these tyrosine motifs become phosphorylated and prevent AP2-
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mediated CTLA-4 internalization leading to CTLA-4 accumula-
tion on the cell surface [26,27,28,29].
The mechanism(s) underlying sustained HIV-1 replication in
activated T cells that express high levels of molecules such as
CTLA-4 have yet to be elucidated. Here, we show that HIV-1 Nef
protein down-regulates surface and total expression of CTLA-4 by
targeting this negative molecule to lysosomal degradation.
Materials and Methods
Cells
The 293T and HeLa cell lines were obtained from ATCC. Cells
were kept in DMEM medium, 10% FCS and penicillin/
streptomycin (Gibco-Life Technologies) and maintained at 37uC
and 5% CO2.
Antibodies
For FACS analysis on 293T cells we used anti-CD4 PE
antibody (BD) and biotinylated Goat anti-CTLA-4 antibody from
R&D Systems (used in combination with Streptavidine-APC).
Anti-Nef and anti-CTLA-4 antibodies used in Western blot
analysis were homemade by injecting rabbits with full length of
these proteins fused to GST. Both homemade anti-CTLA-4 and
anti-Nef polyclonal antibodies recognized the purified forms of
GST-fused CTLA-4 and Nef proteins that were used to immunize
rabbits. These antibodies also reacted positively with CTLA-4 and
Nef transfected but not un-transfected cells and recognized
proteins with the expected molecular weights of 30–34 kD for
CTLA-4 and 27 kD for Nef. Anti-human CD4 antibody for
Western blotting was purchased from RDI and mouse anti-b-actin
antibody was purchased from Sigma. For confocal microscopy
experiments, all secondary rabbit anti-mouse antibodies, anti-
FLAG conjugated with Alexa 568, mouse anti-goat conjugated
with Alexa 488, and transferrin labeled with Alexa 633 were
purchased from Molecular probes.
Nef and CTLA-4 Vectors
The CTLA-4 eukaryotic vector was synthesized by inserting the
CTLA-4 coding sequence by PCR into the EcoR1 and Xba1
restriction sites of pCDNA3 (Invitrogen). The primers used were
CTLA-4 5p/EcoRI: 59- CATCGAATTCATGGCTTGCCTTG
G-39 and CTLA-4 3p/XbaI: 59-TGCTCTAGATCAATTGA
TGGG-39. The CD4 eukaryotic expression vector was generated
in our laboratory. The CD4 cDNA was cloned in SR-alpha
expression vector under the control of the CMV promoter.
The Nef-FLAG expression vector used was pCMVtag4A vector
obtained from Invitrogen. Nef was cloned using 59EcoR1
and 39HindIII restriction sites. The primers used were:
NefCMV5p/EcoRI:59-CGGAATTCCGCCGCCAGGGATG-39
and NefCMV3p/HindIII: 59-GCAAGCTTGCAGTT-39. Nefwt
and Nef mutant vectors used for 293T transfections, including the
negative control, were generated by O. S using pCMV-Nef [30].
Transient transfections
Transfections were performed using calcium phosphate method
[31]. Briefly, 10 million cells were plated in 100 mm2 plates in
10 ml of complete DMEM (10% FCS) 24 hours before transfec-
tion. At the day of transfection, medium was replaced by 10 ml of
fresh warm complete DMEM (10% FCS). For each condition, 15–
45 mg of DNA was mixed with 500 ml of CaCl2 (0.025 M). This
step was followed by the addition of a 1:1 mixture of BBS (BES
buffered solution) previously incubated at room temperature for
20 minutes and then added to cells. BBS 2X was prepared by
adding 50 mM N,Nbis (2-hydroxyethyl)-2-aminoethanesulfonic
acid (BES; Calbiochem), 280 mM NaCl, 1.5 mM Na2HPO4
pH 6.95. Cells were harvested at 48 hours after transfection for
either flow cytometry or Western blotting. We have routinely
monitored our transfection efficacy by including irrelevant GFP
plasmid; the transfection efficiency was always stable between 80–
90%. The transfection efficiency of single transfected proteins was
routinely monitored by determining the protein expression levels
by Western blot analysis and normalization to the housekeeping
gene b-actin.
Biochemical analyses of Nef, CD4 and CTLA-4 proteins
Cells were lysed in lysis buffer containing 250 mM NaCl, 0.5%
NP-40, 50 mM Hepes, 5 mM EDTA and protease inhibitors
(Roche). Purified proteins were then quantified using the BCA kit
(PIERCE). Cell lysates were then ran on 12% SDS gel and
transferred on polyvinylidene fluoride (PVDF) membrane for
Western blot analysis. For anti-CTLA-4 and anti-Nef blots, the
primary antibodies used were homemade rabbit polyclonal
antibodies followed by a step that includes incubation with a
secondary goat anti-rabbit antibody conjugated to horseradish
peroxidase (HRP). Bands were visualized by ECL (Amersham)
then quantified by densitometric analysis using GelEval 1.22
software on images generated from films. The relative intensity of
each band was normalized against b-actin or GAPDH.
Confocal Microscopy
Cells were plated at 50,000 cells per coverslip mounted with
poly-L-Lysin (Sigma) in 6-well plates. Transient transfections were
carried out on these cells on coverslips using pCDNA3/CTLA-4
and/or pCMV/Nef-FLAG vectors. Forty-eight hours after trans-
fection, cells on coverslips were washed with PBS containing
1 mM MgCl2 and fixed with 4% paraformaldehyde (PFA) for
15 min at room temperature. Cells were then washed by PBS and
permeabilized by PBS containing 0.2% triton X-100 for 10 min at
room temperature. After washings, cells were incubated with the
primary and secondary antibodies as indicated in the figure
legends. For CTLA-4 staining, 5 ml of anti-CTLA-4 and 1/50
dilution of secondary antibodies were used. For anti-FLAG, 1 mg
of primary antibody and 1/50 secondary were used. Slides were
then mounted and the images were taken with an LSM 510
META laser scanning confocal microscope (Zeiss) and 63 Plan-
Apochromat objective with a numerical aperture of 1.4. Images
were analyzed using Image J software (National Institute of
Health).
Flow cytometry
To monitor CTLA-4 expression on 293T cells transfected with
CTLA-4, cells were stained with biotinylated goat anti-CTLA-4
antibody for 30 min at 4uC then washed twice with PBS-FBS (2%)
and stained with Streptavidine-APC for 20 min (4uC). For CD4
expression, cells were stained with anti-CD4 PE antibody for
30 min at 4uC. Stained cells were then washed twice with PBS-
FBS (2%) and fixed with 2% paraformaldehyde (in PBS) and
analyzed on BD LSRII flow cytometer.
Statistical Analysis
All p values were calculated by paired t test (two tailed).
Pearson’s correlation coefficient (Rr) was used to determine the co-
localization, segregation or lack of correlation for CTLA-4 and
Nef. Pearson’s correlation coefficient was obtained for each
individual cell. In Pearson’s correlation, the average pixel intensity
values are subtracted from the original intensity values. As a result,
the value of this coefficient ranges from 21 to 1, with a value of
Effect of HIV Nef on CTLA-4
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21 representing a total lack of overlap between pixels from the
images; a value of 1 indicates perfect image registration [32]. A
single sample t test using GraphPad Prism software was performed
to establish whether the correlation coefficient mean value was
significantly different from zero [33].
Results
HIV-1 Nef protein down-regulates CTLA-4
To assess the role of HIV-1 Nef protein in down-regulating
CTLA-4 expression we established a transient transfection system
to co-express human CTLA-4 and HIV-1 Nef (Nefwt) in 293T
cells. A plasmid encompassing Nef in its reverse orientation
(Nefneg) was used as negative control. Expression of Nef protein in
CTLA-4-expressing 293T cells reduced CTLA-4 surface levels by
57–77% (n= 5) compared to cells transfected with Nefneg plasmid
(Figure 1a, left panels). Similarly, co-expression of Nef and
CD4 in 293T cells led, as expected, to significant down-regulation
of CD4 surface levels (80%) (Figure 1b, left panels). Nef-
mediated down-regulation of both CTLA-4 and CD4 was also
established by co-transfecting 293T cells with a GFP-reporter Nef
construct followed by gating on GFP+ cells and determining the
expression levels of CTLA-4 or CD4 (data not shown). Western
blot analysis of total cell lysates was then used to assess whether
CTLA-4 and CD4 down-regulation by Nef was mediated by
protein degradation versus accelerated internalization and/or
intracellular retention. As shown in Figure 1a&b (right panels)
expression of Nef significantly decreased the total pools of both
CTLA-4 and CD4 proteins, most likely by mediating protein
degradation (the two forms of CTLA-4 on the CTLA-4 blot,
Figure 1a right panel, correspond to membrane (30 kD) and
cytosolic moieties (34 kD) [34]).
To test the hypothesis that Nef interacted with the cytoplasmic
tail of CTLA-4 leading to Nef-mediated down-regulation of
CTLA-4, we generated several CTLA-4 mutants known to impact
on CTLA-4 cellular localization, trafficking and degradation.
CTLA-4 Y201A and CTLA-4 Y218G mutants are unable to bind
to the adaptor protein-2 (AP-2) and are expressed primarily on the
cell surface and to a much lesser extent in intracellular
compartments [35,36]. These tyrosine motifs of CTLA-4 cyto-
plasmic tail were targeted by site directed mutagenesis to generate
Y201A, Y218G and a double tyrosine mutated form Y201A
Y218G. Another potential sorting double-leucine motif of CTLA-
4 cytoplasmic tail LL181 was mutated to generate the LL181AA.
We also generated a construct encompassing the CTLA-4
molecule deleted of its cytoplasmic tail (CTLA-4DCT). Mutating
the tyrosine motifs or deleting the cytoplasmic tail resulted in the
expected accumulation of CTLA-4 on the cell surface, due to lack
of internalization signals [26], whereas the LL181AA mutant
decreased CTLA-4 surface expression (Figure 2a). To determine
the ability of Nef to down-regulate these mutated forms of CTLA-
4 we co-transfected 293T cells with Nefwt and CTLA-4 mutants.
Our data shown in Figure 2 (b–d) demonstrated that neither the
tyrosine sorting motifs (CTLA-4 Y201A, CTLA-4 Y218G or
CTLA-4 Y201AY218G) or the mutated leucine (CTLA-4
LL181AA) nor the deleted cytoplasmic tail construct (CTLA-
4DCT) were able to rescue CTLA-4 expression upon co-
transfection with Nefwt, as shown by FACS (Figure 2b&c) or
by Western blotting (Figure 2d). There were no significant
differences in the levels of CTLA-4 down-regulation between the
CTLA-4 wt molecule and the different CTLA-4 mutants. Of note,
the CTLA-4DCT mutant lost reactivity to the polyclonal antibody
used for the Western blotting while retaining reactivity for
antibodies used for the FACS analysis. These experiments show
that increasing the levels of CTLA-4 by deleting or mutating the
cytoplasmic tail did not affect the capacity of Nef to down-regulate
this molecule. Thereby demonstrating that Nef does not require
the CTLA-4 cytoplasmic tail to exert its effect. Our data with the
CTLA-4DCT suggests that Nef down-regulates CTLA-4 expres-
sion mostly by interfering with CTLA-4 localization in intracel-
lular compartments before reaching the plasma membrane instead
of causing CTLA-4 internalization.
Nef-mediated CTLA-4 down-regulation requires motifs in
Nef involved in the interaction with the vacuolar ATPase,
b-COP and the AP-1 sorting complexes
CTLA-4 traffics rapidly between intracellular vesicles and the
plasma membrane, which accounts for its transient low levels of
cell surface expression [37]. We tested a set of Nef mutants known
to interfere with this protein trafficking in intracellular compart-
ments [38]. The DD175 motif is required for the interaction of Nef
with the v-ATPase, an enzyme present in intracellular vesicles that
plays an important role in the maintenance of acidic pH of
vesicular compartments, an essential component of the intracel-
lular proteolytic machinery [39]. The EE155 motif is required for
the interaction of Nef with the Coatomer subunit ß-COP, known
to be involved in the transport of proteins from the ER to the cis-
Golgi compartment [40]. This motif impacts on the late stages of
Nef-dependent CD4 down-regulation [7]. The dileucine motif
LL165 mediates the interaction of Nef with the sorting adaptor
protein AP-1 [6]. To investigate the involvement of these pathways
in the down-modulation of CTLA-4 by Nef, we co-transfected
CTLA-4 and the above listed Nef mutant constructs into 293T
cells. Our Western blot analysis on total lysates from these cells
(Figure 3a) showed that these Nef mutants, DD175GA,
LL165GG and EE155GG had a significantly lower ability to
mediate CTLA-4 degradation compared to Nefwt (p=0.017, 0.04
and 0.02, respectively, Figure 3b, n=3). However, among the
three Nef mutants, LL165GG had a higher capacity to down-
regulate CTLA-4 compared to DD175GA and EE155GG (57% vs
22 and 26% mediated CTLA-4 down-regulation, respectively).
Altogether, these data indicated that Nef down-modulates
CTLA-4 through a mechanism that requires the interaction of
Nef with the sorting adaptor protein AP-1, the v-ATPase as well as
with the b-COP subunit. This also suggested that cellular
compartments where interaction between CTLA-4 and Nef takes
place are likely to be endosomes and lysosomes, where the v-
ATPase is active [41].
Lysosomal function is required for Nef-induced down-
regulation of CTLA-4
Results in Figure 3 suggested that Nef-induced CTLA-4 down-
regulation was likely mediated by protein degradation in lysosomes
since mutation of the v-ATPase-binding motif of Nef (DD175GA)
rescued CTLA-4 expression. To confirm the role of acidic
compartments in Nef-induced CTLA-4 down-regulation, we
investigated the impact of Nef on CTLA-4 expression in the
presence of Concanamycin A, a specific inhibitor of the vacuolar
ATPase [42]. Similar experiments were performed in the presence
of the weak-base amine ammonium chloride (NH4Cl) known to
inhibit the lysosomal machinery by increasing the pH of endocytic
and lysosomal vesicles [43,44,45]. 293T cells co-transfected with
CTLA-4 (or CD4) and Nefwt were treated with increasing
concentrations of Concanamycin A or NH4Cl. Treatment of
293T cells expressing Nefwt and CTLA-4 with 1, 3, 5, 10 and
20 nM Concanamycin A increased, in a dose-dependent manner,
the levels of CTLA-4 expression as measured by the frequency of
Effect of HIV Nef on CTLA-4
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CTLA-4+ cells, from 44% to 72% (Figure 4a, lower panels &
4b, left panel). In contrast, treatment with Concanamycin A of
293T cells co-transfected with CD4 and Nefwt did not rescue CD4
surface expression (Figure 4b, right panel). However, at higher
concentrations (20 nM) of Concanamycin A, increased-expression
of CD4 protein was only observed with biochemical analysis on
total cell lysates (Figure 4c) suggesting the accumulation of CD4
in intracellular compartments, consistent with earlier observations
by other groups [46].
Ammonium chloride, a lysosomal inhibitor, treatment of 293T
cells expressing Nefwt and CTLA-4 also increased the total pool of
CTLA-4 by 2.7 fold (Figure 4d for Western blotting and 4e
for surface expression by FACS analysis). Of note, we also
observed a dose-dependent accumulation of the total molecular
pool of CTLA-4 in cells co-transfected with Nefneg vector treated
with either Concanamycin A (Figure 4a, upper panels) or with
NH4Cl (Figure 4d&e), most likely resulting from the inhibition of
steady-state degradation of CTLA-4. As expected, the expression
of both CTLA-4 and CD4 was indeed down-regulated in this
transfection system in the absence of both inhibitors (Figure 4a–
e).
Altogether, our results showed that CTLA-4 is down-regulated
by lysosomal degradation as previously shown for CD4. However,
we provide evidence herein that significant differences exist in the
mechanisms leading to the down-regulation of the two molecules
as CTLA-4 re-circulates to the cell surface following treatment
with lysosomal inhibitors whereas, CD4 does not and likely
accumulates in intracellular compartments.
Nef and CTLA-4 co-localize in early and recycling
endosomes
The results described above suggested that Nef and CTLA-4
most likely co-localize in intracellular compartments where protein
degradation typically occurs including lysosomes. In order to
confirm this hypothesis, we monitored the intracellular localization
of both proteins by confocal microscopy in transiently transfected
HeLa cells. The transferrin receptor (Trf) was used as a marker for
early and recycling endosomes [47], which is the compartment
most likely involved in the initial Nef-CTLA-4 interaction. CTLA-
4 is known to reside in intracellular endocytic compartments prior
to its translocation to the plasma membrane [48]. Confocal
microscopy analysis confirmed the presence of CTLA-4 in specific
intracellular granules (endosomes) where the Trf, a marker of early
Figure 1. Nef-mediated CTLA-4 down-regulation. Transient co-expression of CTLA-4 and Nef in 293T cells. a) Left panels: Surface expression of
CTLA-4 analyzed by FACS following staining of 293T cells co-transfected with CTLA-4 and either Nefneg or Nefwt vectors. Right panel: Western blotting
analysis on total cell lysates from 293T cells mock-transfected or co-transfected with CTLA-4 and either Nefneg or Nefwt vectors (Arbitrary
Densitometric units normalized to ß-actin are shown above corresponding lanes. b) Co-transfection of 293T cells with CD4 and either Nefneg or Nefwt
vectors (Left and Right Panels as shown in a). * Refers to the corresponding MW on the SDS gel.
doi:10.1371/journal.pone.0054295.g001
Effect of HIV Nef on CTLA-4
PLOS ONE | www.plosone.org 4 January 2013 | Volume 8 | Issue 1 | e54295
Figure 2. The cytoplasmic tail of CTLA-4 is dispensable for Nef-induced CTLA-4 down-regulation. a) Accumulation of CTLA-4 on the cell
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endosomes [47], is expressed (Figure 5a). As expected from our
mutagenesis studies, these Trf+ early and recycling endosomes
showed significant co-localization between Nef and CTLA-4. The
scatter diagram shows the intensity of fluorescence for CTLA-4 (Y
axis) and Nef (X axis) in one single representative cell (Figure 5b).
The white granules (Figure 5a lower panels last picture)
depict the co-localization of Nef, CTLA-4 and Trf. Quantification
of CTLA-4 and Nef co-localization was assessed in multiple
independent cells (Figure 5c) (n = 16 and a Pearson coefficient
value of 0.6, p,0.0001).
Previous results (Figure 2) showing that deletion of the
cytoplasmic tail of CTLA-4 did not affect the capacity of Nef to
down-regulate CTLA-4, indicated that the interaction between the
two molecules occurs mostly in intracellular compartments. This
was confirmed by confocal microscopy visualization, since the co-
localization between CTLA-4 and Nef occurred mostly in
intracellular compartments and to a lesser extent at the plasma
membrane (yellow granules that indicate Nef (red) and CTLA-4
(green) interaction are primarily present in intracellular compart-
ments). This was also different from what was described for CD4
as Nef was previously shown to interfere with CD4 expression at
the plasma membrane [49]. Together, these results showed that
Nef co-localizes with CTLA-4 in intracellular acidic compart-
ments, most likely lysosomes, where accelerated degradation of
CTLA-4 occurs.
Discussion
In this study we provide first line of evidence that HIV Nef
down-regulates CTLA-4 expression at the cell surface by
interacting with CTLA-4 in intracellular compartments including
endosomes and lysosomes. The down-regulation of CTLA-4 by
Nef, early in acute infection when most activated T cells express
CTLA-4 at the cell surface [50,51] could provide an important
mechanism to circumvent the physiological effect of CTLA-4 i.e.
inhibition of T cell activation and HIV replication, and to allow
viral dissemination.
Nef proteins from virtually all primate lentiviruses modulate the
expression of a large number of cell surface proteins including
CD4 [2,52,53,54,55,56] and MHC I molecules [10,57] through
multiple mechanisms. We show here that Nef mediates CTLA-4
and CD4 down-regulation via distinct mechanisms. The CTLA-4
cytoplasmic tail was dispensable for this new function of Nef. In
surface after transfection with CTLA-4 Y201AY218G and CTLA-4DCT mutants and lower expression after transfection with CTLA-4 LL181AA. Black solid
histograms represent the isotype controls. Grey solid histograms represent the expression of CTLA-4 Wt. Black empty histograms represent CTLA-4
mutants. Numbers in inset represent the MFI of CTLA-4 mutant/CTLA-4 Wt. b) Surface expression levels of the different mutants of CTLA-4 with
(empty histograms) or without (filled histograms) Nef expression as measured by flow cytometry. The numbers in inset represent the MFI of CTLA-4
under Nefwt/Nefneg co-expression. c) MFI of surface CTLA-4 analyzed by FACS under Nefneg or Nefwt co-expression (mean of three independent
experiments). The p values were calculated comparing values of CTLA-4 MFI under Nefwt co-transfection relative to Nefneg co-transfection. d) Western
blot analysis showing the total expressions of CTLA-4 Wt and CTLA-4 mutated forms after co-transfection with Nefneg (2) or Nefwt (+) in 293T cells. *
Refers to the corresponding MW on the SDS gel.
doi:10.1371/journal.pone.0054295.g002
Figure 3. CTLA-4 down-regulation by Nef requires motifs in Nef involved in the interaction with the vacuolar ATPase, b-COP and
the AP-1 sorting complexes. a) Total expression levels of CTLA-4 in 293T cells after co-transfection with Nefwt or Nef mutants by Western blot.
Numbers above the Nef blot represent the Nef densitometric units normalized to the ß-actin and showing similar expression levels for the different
Nef constructs. b) Densitometric results, normalized to the ß-actin, are presented as mean percentages of CTLA-4 expression after co-transfection
with Nefwt or Nef mutants and normalization to the negative control (Nefneg) from 3 independent experiments. The p values are calculated using the
percentage of CTLA-4 expression under co-transfection with each of the Nef mutants relative to CTLA-4 expression under Nefwt co-transfection. *
Refers to the corresponding MW on the SDS gel.
doi:10.1371/journal.pone.0054295.g003
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Figure 4. Lysosomal function is required for Nef-induced down-regulation of CTLA-4. a) CTLA-4 surface expression levels on 293T cells co-
transfected with Nefneg (upper panels) or Nefwt (lower panels) after treatment with increasing concentrations of Concanamycin A. Grey solid
histograms represent the unstained controls. Grey empty histograms represent Mock-transfected cells (stained with anti-CTLA-4 antibody) and Solid
Effect of HIV Nef on CTLA-4
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contrast, the CD4 cytoplasmic tail was shown to be required for
CD4 degradation by Nef as CD4DCT or a chimera between the
CD4 extracellular and the CD8 intracellular domains are resistant
to Nef-induced down-regulation [53,58]. We also showed that Nef
interacts with CTLA-4 in intracellular compartments. This was
confirmed by our confocal microscopy visualization showing that
most Nef/CTLA-4 interactions occurred in early and recycling
endosomes with very low levels of co-localization of these two
Black histograms represent CTLA-4 and either Nefneg (upper panels) or Nefwt (lower panels) co-transfected cells. b) Percentage of CTLA-4+ cells (left
panel) and CD4+ cells (right panel) from the same experiment at different concentrations of Concanamycin A (0–20 nM). Solid line represents CTLA-4
or CD4 under Nefneg and dotted line represents CTLA-4 or CD4 under Nefwt co-transfection. c) Rescue of total CD4 protein levels by Concanamycin A
treatment. Total lysates from 293T cells co-transfected with CD4 and Nefneg or Nefwt and treated with increasing concentrations of Concanamycin A
(1–20 nM). Numbers on top of CD4 blot represent arbitrary densitometric units after normalization to the b-actin. d) Western blot analysis for total
lysates from 293T cells co-transfected with CTLA-4 and either Nefneg or Nefwt vectors and treated with increasing concentrations of NH4Cl (0–20 mM)
(n = 2). Numbers on the CTLA-4 Western blot represent arbitrary units for CTLA-4 protein expression levels after normalization to b-actin. e) FACS
analysis on 293T cells showing CTLA-4 surface levels under Nefneg (upper panels) and Nefwt (lower panels) co-expression in the presence or absence
of NH4Cl. * Refers to the corresponding MW on the SDS gel.
doi:10.1371/journal.pone.0054295.g004
Figure 5. Nef and CTLA-4 co-localize in early and recycling endosomes. a) HeLa cells transfected only with a FLAG-Nef expression vector
(upper panels) or co-transfected (lower panels) with CTLA-4 expressing vector were incubated with Alexa 633 labeled transferrin (blue), CTLA-4
specific antibody (green) and FLAG-Nef antibody (red). The extreme left panels show a transmission light field. The middle lower panel shows the co-
localization between Nef and CTLA-4 (yellow color results from merging green (CTLA-4) and red (Nef)). The extreme right lower panel shows the co-
localization of the three proteins; CTLA-4, Nef and transferrin together (the white color is a combination of green (CTLA-4), red (Nef) and blue
(transferrin)), Bar = 20 mm. b) Scatter diagram showing the intensity of the CTLA-4-Alexa-fluor 488 (Y-axis) and Nef-Alexa-fluor 546 (X-axis). c) Levels of
co-localization between CTLA-4 and Nef is represented by the mean Pearson’s correlation coefficient (Rr) (n = 16, 9 fields).
doi:10.1371/journal.pone.0054295.g005
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molecules at the plasma membrane (Figure 5). The low levels of
CTLA-4 at the cell surface could likely explain the lack of co-
localization between CTLA-4 and Nef at the plasma membrane,
although CTLA-4 mutants, known to be highly expressed at the
cell surface, were still down-regulated by Nef to levels similar to
those of the wt molecule. Our results suggest that CTLA-4 is
directed for degradation in the endosomal/lysosomal compart-
ment prior to reaching the plasma membrane, thus highlighting a
major difference in the mechanisms that lead to Nef-mediated
degradation of CTLA-4 versus CD4.
Despite the above listed differences, similarities were also
observed in the mechanisms of Nef-mediated down-regulation of
CTLA-4 and CD-4. Both mechanisms required Nef motifs known
to be involved in vesicle trafficking. The double aspartic acid
DD175 of Nef is involved in the interaction of Nef with the
catalytic subunit of vacuolar ATPase (vATPase), originally known
as Nef binding protein 1 or NBP1, an essential component of
lysosome degradation machinery [55]. Binding to the vATPase
was shown to be required for the successful interaction of Nef with
the endocytic machinery by connecting Nef to the m2 chain of AP-
2 adaptor protein [59]. Similar to CD4 down-regulation, the
DD175GA mutant completely abolished the capacity of Nef to
modulate CTLA-4 expression, suggesting that the major mecha-
nism leading to CTLA-4 down-regulation by Nef is protein
degradation and not just retention in intracellular compartments.
This is supported by our results showing that Nef expression leads
to a major reduction in the total intracellular pool of CTLA-4
molecules. Moreover CTLA-4 expression was indeed rescued
when weak-base amines were used to neutralize the lysosomal
acidity or to inhibit the vATPase activity (Figure 4). Importantly,
in contrast to CD4, treatment with pH-neutralizing agents rescued
CTLA-4 surface expression, thus highlighting another difference
between Nef-mediated down-regulation of CD4 and CTLA-4.
Together, our study reveals a novel potential mechanism for
HIV pathogenesis by which Nef-mediated CTLA-4 down-
regulation may decrease the threshold of T cell activation, a
critical step for HIV-1 replication and dissemination. Nef-
mediated down-regulation of CTLA-4 on the cell surface of
infected cells may also contribute to the global hyperimmune
activation, a hallmark of HIV infection. In line with, Nef was
shown to be exported from infected cells through accelerated
release of Nef-containing exosomes [60]. Extracellular Nef targets
bystander CD4+ T cells for apoptosis [61] and also B cells for the
suppression of immunoglobulin class switching [62]. The uptake of
Nef by bystander CD4+ T cells may result in the down-regulation
of CTLA-4 on the cell surface from non-infected cells leading to
global sustained hyperimmune activation and increased viral
replication. Interestingly, work by Cecchinato et al. [63] on SIV-
infected non-human primates (NPHs) demonstrated that antago-
nizing CTLA-4 effect by blocking CTLA-4 with specific antibodies
prior to and following SIV challenge led to hyperimmune
activation and increased viral replication. Most importantly, this
treatment decreased the responsiveness to antiretroviral therapy
and abrogated the ability of therapeutic T cell vaccines to decrease
the viral load set point. This effect is likely a consequence of the
lack of CTLA-4 binding to its ligands leading to substantial
increase of activated CD4+ T cells and subsequent infection with
SIV. Therefore, CTLA-4 evidently plays a physiological role in
limiting viral replication and/or dissemination and that Nef-
mediated down-regulation of CTLA-4 is likely to counteract this
function.
In conclusion, our findings showing that HIV-1 Nef protein
down-regulates the negative modulator CTLA-4 represent a novel
mechanism for HIV-1 pathogenesis that is likely involved in the
enhancement of T cell activation and T cell turnover, two key
cellular functions that are important for HIV-1 replication and
dissemination. HIV-1 Nef is subject to high sequence variation
during the course of infection and among infected individuals. The
ability of HV-1 Nef to modulate CTLA-4 expression may be
different between viral strains and may be linked to the course of
disease progression. Our study opens the path for this new type of
investigation, with a particular focus on differences in HIV Nef
immunoregulatory functions between transmitted/founder versus
chronic viruses and between subjects with slow versus rapid disease
progression.
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